Cipher Pharmaceuticals Inc. (OTCMKTS:CPHRF – Get Free Report) (TSE:CPH) shares crossed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $2.81 and traded as high as $3.34. Cipher Pharmaceuticals shares last traded at $3.30, with a volume of 8,400 shares.
Analysts Set New Price Targets
Separately, Stifel Nicolaus upgraded Cipher Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, June 1st.
Cipher Pharmaceuticals Price Performance
About Cipher Pharmaceuticals
Cipher Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, which is indicated for the treatment of palpable or moderately thick hyperkeratotic actinic keratosis; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome.
- Five stocks we like better than Cipher Pharmaceuticals
- The Significance of Brokerage Rankings in Stock Selection
- Is Enbridge Stock Too Cheap to Pass Up Now?
- Your Comprehensive Guide to Investing in Bank Stocks
- 5 Best REIT Alternatives for Passive Real Estate Income
- Stock Market Sectors: What Are They and How Many Are There?
- 5 Reasons Kroger Should Be On Every Income Investor Watchlist
Receive News & Ratings for Cipher Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cipher Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.